Kamada Ltd. KMDA
Set alert
At close · Oct 30
After hours · Oct 30, 7:36 PM ET
- YTD
- +9.07%
- 1 year
- +12.90%
- Open
- 7.88
- Prev close
- 7.95
- Mkt cap
- 444.37M
- Vol
- 47.51K
- Avg vol
- 126.00K
- EPS
- 0.38
- P/E
- 20.26
- Div yield
- 0.00%
More statistics
- Low
- 7.67
- High
- 7.88
- Forward P/E
- 19.52
- Beta
- 0.20
- Short ratio
- 0.94
- Inst. own
- 50.10%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.77
- 200-d avg
- 5.52
- 1y target
- 14.67
News
1 week ago globenewswire.com
Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026
REHOVOT, Israel and HOBOKEN, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
-
3 weeks ago benzinga.com
Kamada Expands Biosimilar Portfolio With Commercial Launch Of Two Additional New Products In Israel, Adding To Existing Portfolio Of Two Products
Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty…
3 weeks ago globenewswire.com
Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel
Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate Approximately $10 Million in Annual Revenue in 2028 and Approximately $20 Million-$25…
1 month ago defenseworld.net
Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth
Kamada (NASDAQ: KMDA) outlined its growth strategy, product portfolio and financial outlook during a company presentation, emphasizing demand for specialty plasma-derived therapies and a plan to…
1 month ago marketbeat.com
Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth
Kamada NASDAQ: KMDA outlined its growth strategy, product portfolio and financial outlook during a company presentation, emphasizing demand for specialty plasma-derived therapies and a plan to expand…
1 month ago globenewswire.com
CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand
U.S. Centers for Disease Control and Prevention (CDC) Reports a Significant Year-Over-Year Increase in Nationwide Rabies Exposures and Rabies Immunoglobulin Utilization KedRAB is One of Only Two…
1 month ago globenewswire.com
Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated…
1 month ago globenewswire.com
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
REHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed…
2 months ago globenewswire.com
Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026
Dividend to be Paid Consistent with the Company's Cash Dividend Policy Dividend to be Paid Consistent with the Company's Cash Dividend Policy
2 months ago zacks.com
Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"
Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
2 months ago zacks.com
KMDA or PRTA: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Prothena (PRTA). But which of these two companies is the best option for those looking for…
2 months ago zacks.com
Wall Street Analysts Think Kamada (KMDA) Could Surge 79.06%: Read This Before Placing a Bet
The consensus price target hints at a 79.1% upside potential for Kamada (KMDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate…
2 months ago seekingalpha.com
Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript
Kamada Ltd. (KMDA) Q2 2026 Earnings Call Transcript
2 months ago zacks.com
Kamada (KMDA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Kamada (KMDA) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street…
2 months ago zacks.com
Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates
Kamada (KMDA) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.13 per share a year ago.
-
2 months ago benzinga.com
Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M vs $202.048M Est
Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000 million-$205.000 million vs $202.048 million estimate.
-
2 months ago benzinga.com
Kamada Q2 EPS $0.16 Beats $0.12 Estimate, Sales $54.921M Beat $50.657M Estimate
Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.12 by 33.33 percent. This is a 23.08 percent increase over earnings of $0.13 per…
2 months ago globenewswire.com
Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance
REHOVOT, Israel and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for…
2 months ago globenewswire.com
Kamada Announces Planned Transition of Chief Financial Officer
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for…
2 months ago globenewswire.com
Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
3 months ago defenseworld.net
Reviewing InflaRx (NASDAQ:IFRX) and Kamada (NASDAQ:KMDA)
Kamada (NASDAQ: KMDA - Get Free Report) and InflaRx (NASDAQ: IFRX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses…
-
3 months ago benzinga.com
Kamada Signs $50M Plasma Supply Agreement With Biopharma Partner Through Texas Centers, Commercial Sales Starting Q4 2026
Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty…
3 months ago globenewswire.com
Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies
REHOVOT, Israel and HOBOKEN, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
-
3 months ago benzinga.com
Kamada Highlights Results Of An Investigator-initiated Study Of Cytogam, The Company’s Cytomegalovirus Immune Globulin, In The Management Of Cytomegalovirus In Solid Organ Transplantation
Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty…
3 months ago globenewswire.com
Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
Findings from analyses of CMV high-risk lung transplant recipients suggest CYTOGAM use is associated with improved clinical outcomes, supporting increased CYTOGAM utilization Findings from analyses…
-
5 months ago benzinga.com
Kamada Announces FDA Approval Of New In-House Rapid Fluorescent Focus Inhibition Test Laboratory
Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty…
5 months ago benzinga.com
Kamada Q1 2026 Earnings Call: Complete Transcript
Kamada Q1 2026 Earnings Call: Complete Transcript
-
5 months ago benzinga.com
Kamada Affirms FY2026 Sales Guidance of $200.000M-$205.000M vs $201.581M Est
Kamada (NASDAQ:KMDA) affirms FY2026 sales outlook from $200.000 million-$205.000 million to $200.000 million-$205.000 million vs $201.581 million estimate.
-
5 months ago benzinga.com
Kamada Q1 EPS $0.07 Misses $0.12 Estimate, Sales $45.240M Miss $46.722M Estimate
Kamada (NASDAQ:KMDA) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.12 by 41.67 percent. This is unchanged from the same period last year. The…
-
7 months ago benzinga.com
Earnings Scheduled For March 11, 2026
Earnings Scheduled For March 11, 2026
11 months ago benzinga.com
Earnings Scheduled For November 10, 2025
Earnings Scheduled For November 10, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
1 year ago benzinga.com
Earnings Scheduled For August 13, 2025
Earnings Scheduled For August 13, 2025
-
1 year ago benzinga.com
Earnings Scheduled For November 13, 2024
Earnings Scheduled For November 13, 2024
-
2 years ago benzinga.com
Earnings Scheduled For March 6, 2024
Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million.
-
2 years ago benzinga.com
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
-
3 years ago benzinga.com
Earnings Scheduled For May 17, 2023
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is likely to report quarterly earnings at $0.14 per share on revenue of $369.35 million.
-
3 years ago benzinga.com
Earnings Scheduled For March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 241 companies hit new 52-week lows.
-
3 years ago benzinga.com
Earnings Scheduled For November 22, 2022
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its third quarter.
-
4 years ago benzinga.com
Earnings Scheduled For August 17, 2022
Companies Reporting Before The Bell • Children's Place (NASDAQ:PLCE) is expected to report earnings for its second quarter.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 215 companies set new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 1043 companies hit new 52-week lows.
-
4 years ago benzinga.com
Earnings Scheduled For March 15, 2022
Companies Reporting Before The Bell • IDEAYA Biosciences (NASDAQ:IDYA) is likely to report quarterly loss at $0.31 per share on revenue of $8.98 million.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Thursday morning, 173 companies reached new 52-week lows.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday morning, 282 companies set new 52-week lows.
-
5 years ago benzinga.com
Earnings Scheduled For August 11, 2021
Companies Reporting Before The Bell • Wireless Telecom Group (AMEX:WTT) is likely to report earnings for its second quarter.